On October 2, 2026 Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, reported that a poster will be presented at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper), taking place November 4-8, 2026, in Phoenix, AZ, demonstrating that atebimetinib enhances PD-1 checkpoint blockade in RAS mutant tumor models. These findings support Immuneering’s plans to conduct a Phase 2 study of atebimetinib in combination with PD-1 blockade in patients with lung cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Presentation Details:
Title: Cyclic disruption of the mitogen-activated protein kinase (MAPK) pathway by the pulsatile MEK inhibitor, Atebimetinib, enhances PD-1 checkpoint blockade in RAS mutant tumors.
Lead author: Amy E. Axel, Immuneering
Abstract Number: 377
Date and Time: Friday, November 6, 2026, 10:00 a.m. MT
Following presentation, the poster will be available on the publications section of Immuneering’s website at View Source
(Press release, Immuneering, OCT 2, 2026, View Source [SID1234671242])